Evidence map›Paper›PMID 25533796›Full record

ReviewNature reviews. Cardiology2015

Cardiorheumatology: cardiac involvement in systemic rheumatic disease.

Megha Prasad, Joerg Hermann, Sherine E Gabriel, Cornelia M Weyand, Sharon Mulvagh, Rekha Mankad, Jae K Oh, Eric L Matteson, Amir Lerman

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04056039 (Efficacy of Atorvastatin vs Colchicine in Decrease of Troponin I of High Sensitivity as a Biomarker of Myocardial Damage in Patients With Rheumatoid Arthritis With Severe Activity.), which is not on this map. Cited by 88 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 5 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04056039 phase2completedstarted 2018, after this paper: background citation

Efficacy of Atorvastatin vs Colchicine in Decrease of Troponin I of High Sensitivity as a Biomarker of Myocardial Damage in Patients With Rheumatoid Arthritis With Severe Activity.

Ran2018Enrolled60Registered outcomes3Posted comparisons0ConditionsArthritis, Rheumatoid, Cardiovascular DiseasesArmsAtorvastatin, Colchicine
PMID 27580061PMID 25662717PMID 24820145PMID 24720919PMID 20053272PMID 24093840PMID 23265346PMID 18926169PMID 22986289PMID 16972704PMID 15189396PMID 11358070other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 5 syntheses or guidelines pooled it, 203 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Myocarditis-Associated Cardiogenic Shock: A Nationwide Multicenter Study.Journal of the American Heart Association · 2025
    Article
  12. Mendelian randomization of autoimmune hepatitis and cardiovascular diseases.American heart journal plus : cardiology research and practice · 2025
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Megha PrasadDivision of Cardiovascular Disease, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Joerg HermannDivision of Cardiovascular Disease, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Sherine E GabrielDivision of Rheumatology and Department of Health Sciences Research, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Cornelia M WeyandDivision of Rheumatology, Stanford University, 300 Pasteur Drive, A100 MC5309, Stanford, CA 94305, USA.
Sharon MulvaghDivision of Cardiovascular Disease, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Rekha MankadDivision of Cardiovascular Disease, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Jae K OhDivision of Cardiovascular Disease, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Eric L MattesonDivision of Rheumatology and Department of Health Sciences Research, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Amir LermanDivision of Cardiovascular Disease, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Mayo Clinic · USStanford University · US

Funding

Vascular specific ACE expression and atherosclerosisP01HL058000 · EMORY UNIVERSITY · 1998 to 2005
$8.6M
Oligoclonal T Cell Expansion &Rheumatoid ArthritisR01AR042527 · NIAMS · MAYO CLINIC ROCHESTER · PI Cornelia M. Weyand · 1993 to 2022
$1.7M
CD8 T CELLS IN RHEUMATOID SYNOVITISR01AI044142 · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · 1999 to 2003
$996k
DNA Repair and Mitochondrial Dysfunction in T Cell AgingR01AI108906 · NIAID · MAYO CLINIC ROCHESTER · PI Cornelia M. Weyand · 2022 to 2024
$919k
The NOTCH Signaling Pathway in Large Vessel VasculitisR01HL117913 · MAYO CLINIC ROCHESTER · 2025 to 2025
$630k
NHLBI NIH HHS P01 HL058000NHLBI NIH HHS R01 HL117913NIAID NIH HHS R01 AI044142NIAID NIH HHS R01 AI108906NIAMS NIH HHS R01 AR042527
6 · The paper itself

Abstract

Autoimmune rheumatic diseases can affect the cardiac vasculature, valves, myocardium, pericardium, and conduction system, leading to a plethora of cardiovascular manifestations that can remain clinically silent or lead to substantial cardiovascular morbidity and mortality. Although the high risk of cardiovascular pathology in patients with autoimmune inflammatory rheumatological diseases is not owing to atherosclerosis alone, this particular condition contributes substantially to cardiovascular morbidity and mortality-the degree of coronary atherosclerosis observed in patients with rheumatic diseases can be as accelerated, diffuse, and extensive as in patients with diabetes mellitus. The high risk of atherosclerosis is not solely attributable to traditional cardiovascular risk factors: dysfunctional immune responses, a hallmark of patients with rheumatic disorders, are thought to cause chronic tissue-destructive inflammation. Prompt recognition of cardiovascular abnormalities is needed for timely and appropriate management, and aggressive control of traditional risk factors remains imperative in patients with rheumatic diseases. Moreover, therapies directed towards inflammatory process are crucial to reduce cardiovascular disease morbidity and mortality. In this Review, we examine the multiple cardiovascular manifestations in patients with rheumatological disorders, their underlying pathophysiology, and available management strategies, with particular emphasis on the vascular aspects of the emerging field of 'cardiorheumatology'.

Indexed as

Arthritis, RheumatoidAtherosclerosisAutoimmune DiseasesCardiovascular DiseasesHumansLupus Erythematosus, SystemicRheumatic Diseases

Identifiers

PMID25533796
PMCPMC4641514
OpenAlexW2015742071

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.